Hospital Universitario Principe De Asturias

Research siteFast reply

Spain Carretera Meco S/n, 28805 Alcala De Henares, Spain

11 trials recruiting
Acute myeloid leukaemia · Arteriosclerosis · Type 2 diabetes mellitus
Adults and children

About Specializations

Hospital Universitario Principe De Asturias in Alcala De Henares, Spain specialises in clinical trials of conditions such as Acute myeloid leukaemia, Arteriosclerosis, Type 2 diabetes mellitus, Cardiovascular disorder, and other specialisations. This site conducts important research.

Main research areas of the site

Endocrinology and Nutrition Research at Hospital Universitario Principe De Asturias

The clinical trial activity at this site focuses on nutritional and metabolic diseases, with particular attention to type 2 diabetes, obesity, and overweight. These studies are aimed at evaluating new treatment options and understanding how better therapies may improve blood sugar control and support weight management in people with metabolic conditions.

Testing a new therapy for type 2 diabetes in people with obesity or overweight
Assessing treatment effectiveness and safety in metabolic disease
Exploring better ways to support long-term care in endocrinology and nutrition

With a small but focused portfolio, the site contributes to research that may help improve everyday management of chronic metabolic disorders.

Hemic and Lymphatic Diseases Research

Another key area of research involves hemic and lymphatic diseases, especially follicular lymphoma. The trials in this field are designed to study the safety and effectiveness of new treatment approaches for adults with untreated lymphoma, with the goal of improving response to therapy and expanding options for cancer care.

Evaluating a new treatment approach for follicular lymphoma
Comparing cancer therapy effectiveness against standard treatment options
Studying safety and tolerability in hematologic oncology

At Hospital Universitario Principe De Asturias, this research supports progress in lymphoma treatment by examining whether newer therapies can offer better outcomes for patients.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Carretera Meco S/n28805 Alcala De HenaresSpain

Open in maps ↗

Recruiting now: 11 trials
Conditions studied: 18

More sites in Alcala De Henares Spain

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

20 clinical trials

Cardiovascular disorder+1

Recruiting

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Study of Zilebesiran Added to Standard Treatment to Reduce Heart Problems in Adults with High Blood Pressure and Heart Disease Risk

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Zilebesiran
Sponsor:Alnylam Pharmaceuticals Inc.

Contact Research Centre

Arteriosclerosis

Recruiting

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Clazakizumab
Sponsor:CSL Behring LLC

Contact Research Centre

Chronic obstructive pulmonary disease

Recruiting

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

A study to evaluate the efficacy and safety of depemokimab and salbutamol sulfate in patients with chronic obstructive pulmonary disease and type 2 inflammation.

Registered drug

Spain

Participants:18–64 years · 65+ years
Substances:Depemokimab
Sponsor:Glaxosmithkline Research & Development Limited

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo

A study to evaluate the safety and efficacy of ivosidenib, decitabine, and cedazuridine in adults with newly diagnosed acute myeloid leukemia who are older than 60 or cannot receive intensive chemotherapy.

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Cedazuridine
Sponsor:Fundacion PETHEMA

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

Study of Revumenib and Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia with NPM1 Gene Mutation

Registered drug

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Syndax Pharmaceuticals Inc.

Contact Research Centre

Acute myeloid leukaemia

Recruiting

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

A study comparing venetoclax, azacitidine, and quizartinib versus venetoclax and azacitidine in newly diagnosed acute myeloid leukemia patients not suitable for standard chemotherapy

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Quizartinib Dihydrochloride
Sponsor:Fundacion PETHEMA

Contact Research Centre

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

Spain

Participants:0–17 years · 18–64 years
Substances:Teplizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

Recruiting

Registered drugNo placebo

Study on the Effectiveness of Moxifloxacin and Drug Combination for Treating Bone Implant Infections in Patients with Long Bone Fractures

Registered drugNo placebo

Spain

Participants:0–17 years · 18–64 years · 65+ years
Substances:Amoxicillin
Sponsor:Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Contact Research Centre

Colorectal cancer+1

Recruiting

Study on the Effectiveness of Heated Chemotherapy with Mitomycin-C for Patients with Colon Cancer Spread to the Peritoneum After Surgery

Registered drugNo placebo

Study on the Effectiveness of Heated Chemotherapy with Mitomycin-C for Patients with Colon Cancer Spread to the Peritoneum After Surgery

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Mitomycin
Sponsor:Hospital Universitario De Fuenlabrada

Contact Research Centre

Diabetic retinopathy

Recruiting

Study on the Effectiveness of Somatostatin Eye Drops for Patients with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy

Investigational

Study on the Effectiveness of Somatostatin Eye Drops for Patients with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Somatostatin
Sponsor:Bcn Peptides S.A.

Contact Research Centre

Infection prophylaxis

Recruiting

Study on Infection Prevention in Joint Replacement Surgery Using Povidone, Chlorhexidine, and Vancomycin for Adult Patients

Registered drugNo placebo

Study on Infection Prevention in Joint Replacement Surgery Using Povidone, Chlorhexidine, and Vancomycin for Adult Patients

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Benzyl Alcohol
Sponsor:Hamilton Health Sciences Corporation

Contact Research Centre

Arteriosclerosis

Not yet recruiting

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Study of olpasiran to prevent first major cardiovascular events in people with high levels of lipoprotein(a)

Investigational

Spain

Participants:18–64 years · 65+ years
Sponsor:Amgen Inc.

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites